Lena Cerruti1, Nathalie Bleyzac2, Michel Tod3,4,5,6. 1. Pharmacie, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France. 2. EMR3738, Faculté de médecine Lyon-sud, Université Lyon 1, Lyon, France. 3. Pharmacie, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France. michel.tod@univ-lyon1.fr. 4. EMR3738, Faculté de médecine Lyon-sud, Université Lyon 1, Lyon, France. michel.tod@univ-lyon1.fr. 5. Faculté de pharmacie, Université Lyon 1, Lyon, France. michel.tod@univ-lyon1.fr. 6. EMR3738, Faculté de médecine Lyon-sud, BP 12 Chemin du grand revoyet, 69921, Oullins, France. michel.tod@univ-lyon1.fr.
Abstract
BACKGROUND AND OBJECTIVE: A simple approach is proposed to predict drug clearance in children when no paediatric data are available for drugs metabolised by cytochromes. METHODS: The maturation functions of cytochrome activity and binding proteins in plasma were combined with several measures of body size to describe drug clearance increase with age. The complete model and different reduced models were evaluated on a large panel of drug clearance data in children. The parameters of the models were estimated by nonlinear regression. Bias and precision of predictions were determined. RESULTS: Two hundred and ten clearance ratios were available for the analysis, corresponding to 53 drugs mainly eliminated by cytochrome metabolism. The age range was 1.5 day to 16 years and there were 30 values for children aged less than 2 years. Fat-free mass at power 0.75 yielded better results than the other body size descriptor tested. The model with the best fit was based on the fat-free mass ratio, the unbound fraction ratio, maturation functions for cytochromes and no maturation function for clearance by other routes. In children aged less than 2 years, the predictive performances were much better with the final model than with the model based on body surface area. The final model was almost unbiased. CONCLUSIONS: This model allows the calculation of the maintenance dose of drugs eliminated mainly by cytochromes. After external validation, it could be used in children aged less than 2 years. In older children, the model reduces to a simple approach based on body surface area or preferably on fat-free mass at power 0.75. The model is not suitable for preterm neonates.
BACKGROUND AND OBJECTIVE: A simple approach is proposed to predict drug clearance in children when no paediatric data are available for drugs metabolised by cytochromes. METHODS: The maturation functions of cytochrome activity and binding proteins in plasma were combined with several measures of body size to describe drug clearance increase with age. The complete model and different reduced models were evaluated on a large panel of drug clearance data in children. The parameters of the models were estimated by nonlinear regression. Bias and precision of predictions were determined. RESULTS: Two hundred and ten clearance ratios were available for the analysis, corresponding to 53 drugs mainly eliminated by cytochrome metabolism. The age range was 1.5 day to 16 years and there were 30 values for children aged less than 2 years. Fat-free mass at power 0.75 yielded better results than the other body size descriptor tested. The model with the best fit was based on the fat-free mass ratio, the unbound fraction ratio, maturation functions for cytochromes and no maturation function for clearance by other routes. In children aged less than 2 years, the predictive performances were much better with the final model than with the model based on body surface area. The final model was almost unbiased. CONCLUSIONS: This model allows the calculation of the maintenance dose of drugs eliminated mainly by cytochromes. After external validation, it could be used in children aged less than 2 years. In older children, the model reduces to a simple approach based on body surface area or preferably on fat-free mass at power 0.75. The model is not suitable for preterm neonates.
Authors: Sarayut Janmahasatian; Stephen B Duffull; Susan Ash; Leigh C Ward; Nuala M Byrne; Bruce Green Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447
Authors: Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford Journal: Br J Clin Pharmacol Date: 2006-07-21 Impact factor: 4.335
Authors: Marcus Klein; Maria Thomas; Ute Hofmann; Daniel Seehofer; Georg Damm; Ulrich M Zanger Journal: Drug Metab Dispos Date: 2014-12-05 Impact factor: 3.922
Authors: Craig Knox; Vivian Law; Timothy Jewison; Philip Liu; Son Ly; Alex Frolkis; Allison Pon; Kelly Banco; Christine Mak; Vanessa Neveu; Yannick Djoumbou; Roman Eisner; An Chi Guo; David S Wishart Journal: Nucleic Acids Res Date: 2010-11-08 Impact factor: 16.971